Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)

Breast Cancer

Volumn 20, Issue 2, 2013, Pages 174-180

  Artac, Mehmet ^a   Bozcuk, Hakan ^b   Kıyıcı, Aysel ^a   Eren, Orhan Onder ^a   Boruban, Melih Cem ^a   Ozdogan, Mustafa ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Aromatase inhibitors; Hormonal therapy; Leptin; Metastatic breast cancer; Waist to hip ratio; Weight

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; LEPTIN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BONE TUMOR; BREAST TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; SOFT TISSUE TUMOR; SURVIVAL RATE; WAIST HIP RATIO;

ADULT; AGED; AROMATASE INHIBITORS; BONE NEOPLASMS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPTIN; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WAIST-HIP RATIO;

EID: 84884799102     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0322-1     Document Type: Article

References (31)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-42. (Pubitemid 36682823)
2. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(Suppl):S116-24. (Pubitemid 32783340)
3. Longcope C, Baker R, Johnston CC Jr. Androgen and estrogen metabolism: relationship to obesity. Metabolism. 1986;35:235-7. (Pubitemid 16137630)
4. Long JR, Shu XO, Cai Q, Wen W, Kataoka N, Gao YT, et al. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes (Lond). 2007;31(3):418-23.
5. Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno ML, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668-76. (Pubitemid 36935773)
6. Geisler C, Haynes B, Ekse D, Dowsett M, Lønning PE. Total body aromatization in postmenapozal breast cancer patients is strongly correlated to plasma leptin levels. J Streoid Biochem Mol Biol. 2007;104:27-34. (Pubitemid 46412990)
7. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 2002;21:1285-92.
8. Kim Y, Kim SY, Lee JJ, Seo J, Kim YW, Koh SH, et al. Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat. 2006;38(3):126-32.
9. Revillion F, Charlier M, Lhotellier V, Homez L, Giard S, Baranzelli MC, et al. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 2006;12:2088-94.
10. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ. 2007;335:1134. (Pubitemid 350247286)
11. Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, et al. Waist to hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158:963-8. (Pubitemid 37413395)
12. Hollmann M, Runnebaum B, Gerhard I. Impact of waist-hip-ratio and body-mass-index on hormonal and metabolic parameters in young, obese women. Int J Obes Relat Metab Disord. 1997;21:476-83. (Pubitemid 27236966)
13. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdoǧan M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27:58-65. (Pubitemid 38881527)
14. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037-42.
15. Garaulet M, Pérex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143(5):657-66.
16. Artac M, Bozcuk H, Afacan B, Ozdogan M, Samur M. The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer treated with aromatase inhibitors. Breast. 2008;17:418-22.
17. WHO (World Health Organisation). Measuring obesity-classification and description of antropometric data. EUR/ICP/NUT 125-0612. V. Copenhagen: WHO Regional Office for Europe; 1988.
18. Hu FB. Overweight and obesity in women: health risks and consequences. J Womens Health (Larchmt). 2003;12:163-72. (Pubitemid 36546761)
19. Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG. 2006;113:1160-6. (Pubitemid 44401209)
20. Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin. Eur J Cancer. 2011;47:33-43.
21. Stattin P, Söderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86:191-6. (Pubitemid 39070961)
22. Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer. 2006;95(2):153-8. (Pubitemid 44050914)
23. Geisler J, Ekse D, Lonning PE. The aromatase inactivator exemestane decreases plasma leptin levels in postmenopausal breast cancer patients. AACR, 97th Annual Meeting, abstract 420, Washington; 2006.
24. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol. 2005;95:167-72. (Pubitemid 41137307)
25. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol. 2006;102:232-40. (Pubitemid 44750638)
26. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen-receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95:1467-76. (Pubitemid 37279332)
27. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br J Cancer. 2011;104(1):128-37.
28. Grossman ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, Dogan S, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010;29(4):641-53.
29. Söderberg S, Ahren B, Eliasson M, Dinesen B, Olsson T. The association between leptin and proinsulin is lost with central obesity. J Intern Med. 2002;252:14-148. (Pubitemid 34989275)
30. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292-5. (Pubitemid 26033933)
31. Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf). 2007;66(3):440-6. (Pubitemid 46239306)